Masaomi Ikeda, Takanobu Motoshima, Kazuhiro Kurosawa, Yoichi Fujii, Jimpei Miyakawa, Takayuki Kamigaito, Chihiro Hosoda, Hideki Komatsu, Toshikazu Okaneya
The Department of Urology, Toranomon Hospital.
Hinyokika kiyo. Acta urologica Japonica 2013 MarThe objectives of this study were to evaluate the efficacy and toxicity of maintenance intravesical instillation therapy with bacillus Calmette-Guerin (BCG) and epirubicin for non-muscle invasive bladder cancer. From April 1999 to March 2010, 27 eligible patients were enrolled in this study. After receiving one cycle of epirubicin (100 mg/100 ml) by intravesical instillation, all patients received 6 weekly alternate intravesical instillation of BCG (80 mg/50 ml) and epirubicin (50 mg/50 ml), followed by 10 monthly instillations. Among the 27 patients, 19 were men and 8 were women, with a median age of 62.4 years (range, 37-78 years). Tumor pathologic stage was pTa in 25 patients, pT1 in 2 and there were no concomitant carcinoma in situ cases. Median follow-up was 37.1 months (range, 11-82 months). The 3- year recurrence-free and progression-free survival rates were 75.3% and 96.1%, respectively. Furthermore, a high completion rate of 81.5% was achieved in this study. Adverse events of grade 3 or higher occurred in 3 patients (11.1%), 1 patient had anaphylaxis. There were no treatment-related deaths. Maintenance intravesical instillation therapy with BCG and epirubicin is a favorable therapeutic option for non-muscle invasive bladder cancer. Given the safety and benefit profile found in this study, appropriate patient selection is warranted in the future.
Masaomi Ikeda, Takanobu Motoshima, Kazuhiro Kurosawa, Yoichi Fujii, Jimpei Miyakawa, Takayuki Kamigaito, Chihiro Hosoda, Hideki Komatsu, Toshikazu Okaneya. Efficacy and safety of maintenance intravesical instillation therapy with bacillus Calmette-Guerin and epirubicin for non-muscle invasive bladder cancer]. Hinyokika kiyo. Acta urologica Japonica. 2013 Mar;59(3):153-7
PMID: 23633629
View Full Text